Heat Biologics, Inc. (NASDAQ:HTBX) is scheduled to issue its quarterly earnings data on Monday, October 30th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter.
Shares of Heat Biologics, Inc. (NASDAQ HTBX) opened at 0.56 on Friday. The stock’s market capitalization is $20.04 million. Heat Biologics, Inc. has a 52-week low of $0.46 and a 52-week high of $3.35. The stock has a 50 day moving average price of $0.64 and a 200-day moving average price of $0.63.
HTBX has been the subject of several research reports. Griffin Securities initiated coverage on Heat Biologics in a report on Tuesday, September 12th. They set a “buy” rating and a $2.25 price objective for the company. Zacks Investment Research downgraded Heat Biologics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th. ValuEngine downgraded Heat Biologics from a “sell” rating to a “strong sell” rating in a research report on Thursday, July 13th. Finally, Noble Financial reissued a “buy” rating on shares of Heat Biologics in a research report on Tuesday, July 4th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. Heat Biologics presently has an average rating of “Hold” and a consensus price target of $2.13.
TRADEMARK VIOLATION WARNING: This piece was first posted by TrueBlueTribune and is the property of of TrueBlueTribune. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.truebluetribune.com/2017/10/28/heat-biologics-inc-htbx-scheduled-to-post-quarterly-earnings-on-monday.html.
An institutional investor recently raised its position in Heat Biologics stock. Vanguard Group Inc. boosted its position in Heat Biologics, Inc. (NASDAQ:HTBX) by 11.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 661,388 shares of the biopharmaceutical company’s stock after acquiring an additional 70,290 shares during the quarter. Vanguard Group Inc. owned 1.86% of Heat Biologics worth $403,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 8.74% of the company’s stock.
Heat Biologics Company Profile
Heat Biologics, Inc is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT).
Receive News & Ratings for Heat Biologics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heat Biologics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.